Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

التفاصيل البيبلوغرافية
العنوان:	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
المؤلفون:	Lang, Istvan, Brodowicz, Thomas, Ryvo, Larisa, Kahan, Zsuzsanna, Greil, Richard, Beslija, Semir, Stemmer, Salomon M, Kaufman, Bella, Zvirbule, Zanete, Steger, Günther G, Melichar, Bohuslav, Pienkowski, Tadeusz, Sirbu, Daniela, Messinger, Diethelm, Zielinski, Christoph
المصدر:	In Lancet Oncology February 2013 14(2):125-133
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	14702045
DOI:	10.1016/S1470-2045(12)70566-1